Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics

Ligand Pharmaceuticals Incorporated (LGND): $71.65

-1.96 (-2.66%)

POWR Rating

Component Grades













Add LGND to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where LGND ranks best; there it ranks ahead of 90.28% of US stocks.
  • The strongest trend for LGND is in Growth, which has been heading up over the past 178 days.
  • LGND's current lowest rank is in the Stability metric (where it is better than 16.86% of US stocks).

LGND Stock Summary

  • With a year-over-year growth in debt of -65.55%, LIGAND PHARMACEUTICALS INC's debt growth rate surpasses merely 3.77% of about US stocks.
  • Over the past twelve months, LGND has reported earnings growth of -126.39%, putting it ahead of only 12.15% of US stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for LGND comes in at 19.12% -- higher than that of 91.54% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LIGAND PHARMACEUTICALS INC are DUOL, TXG, NVCR, ME, and FROG.
  • Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to

LGND Valuation Summary

  • In comparison to the median Healthcare stock, LGND's price/earnings ratio is 351.72% lower, now standing at -58.4.
  • Over the past 243 months, LGND's EV/EBIT ratio has gone down 52.7.

Below are key valuation metrics over time for LGND.

Stock Date P/S P/B P/E EV/EBIT
LGND 2022-11-25 5.1 1.5 -58.4 -64.7
LGND 2022-11-23 5.1 1.5 -58.0 -64.3
LGND 2022-11-22 5.2 1.5 -59.4 -65.7
LGND 2022-11-21 5.5 1.6 -62.3 -68.7
LGND 2022-11-18 5.4 1.6 -61.4 -67.7
LGND 2022-11-17 5.5 1.6 -62.2 -68.5

LGND Growth Metrics

    Its 5 year revenue growth rate is now at 0.9%.
  • Its 5 year cash and equivalents growth rate is now at 526.74%.
  • Its 2 year revenue growth rate is now at 143.43%.
Over the past 70 months, LGND's revenue has gone up $132,700,000.

The table below shows LGND's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 241.673 112.02 -21.292
2022-06-30 240.42 111.556 -7.973
2022-03-31 267.676 120.055 23.647
2021-12-31 277.133 78.798 57.138
2021-09-30 274.65 51.693 68.315
2021-06-30 251.663 44.413 47.891

LGND's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LGND has a Quality Grade of C, ranking ahead of 59.87% of graded US stocks.
  • LGND's asset turnover comes in at 0.195 -- ranking 202nd of 681 Pharmaceutical Products stocks.
  • NBIX, IRWD, and MNKD are the stocks whose asset turnover ratios are most correlated with LGND.

The table below shows LGND's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.195 0.774 0.067
2021-03-31 0.162 0.837 0.054
2020-12-31 0.148 0.837 0.016
2020-09-30 0.111 0.856 0.006
2020-06-30 0.092 0.862 0.002
2020-03-31 0.073 0.889 -0.026

LGND Price Target

For more insight on analysts targets of LGND, see our LGND price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $207.00 Average Broker Recommendation 1.43 (Moderate Buy)

LGND Stock Price Chart Interactive Chart >

Price chart for LGND

LGND Price/Volume Stats

Current price $71.65 52-week high $164.84
Prev. close $73.61 52-week low $57.77
Day low $71.15 Volume 183,400
Day high $74.66 Avg. volume 150,048
50-day MA $82.89 Dividend yield N/A
200-day MA $93.31 Market Cap 1.21B

Ligand Pharmaceuticals Incorporated (LGND) Company Bio

Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.

LGND Latest News Stream

Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream

Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about LIGAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LGND as an investment opportunity.

15 Most Volatile Stocks to Buy Now

In this article, we discuss the 15 most volatile stocks to buy now. If you want to read about some more volatile stocks, go directly to 5 Most Volatile Stocks to Buy Now. Even though the United States stock market is inextricably linked to the US economy, there are increased fears that the factors contributing […]

Yahoo | November 21, 2022

Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium

COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it had four abstracts accepted as poster presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 6-10 at the Henry B. Gonzalez Convention Center in San Antonio. Two of the posters address the

Yahoo | November 17, 2022

Ligand to Hold Investor and Analyst Day on December 13

SAN DIEGO, November 16, 2022--Ligand to Hold Investor and Analyst Day on December 13

Yahoo | November 16, 2022

Analysts’ Top Healthcare Picks: Agenus (AGEN), Ligand Pharma (LGND)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agenus (AGEN – Research Report) and Ligand Pharma (LGND – Research Report) with bullish sentiments. Agenus (AGEN) In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Agenus, with a price target of $8.00. The company's shares closed last Tuesday at $2.26. According to TipRanks.

Christine Brown on TipRanks | November 8, 2022

Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook

Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.

Yahoo | November 8, 2022

Read More 'LGND' Stories Here

LGND Price Returns

1-mo -18.64%
3-mo -22.45%
6-mo -16.88%
1-year -53.85%
3-year -36.59%
5-year -45.66%
YTD -53.61%
2021 55.31%
2020 -4.64%
2019 -23.15%
2018 -0.90%
2017 34.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8007 seconds.